We next evaluated the impact of a novel plaque-targeted nano-GLP1 agonist at very low doses to allow decoupling of systemic effects in an effort to understand the impact of direct plaque delivery on atherosclerosis. The gene discussed is GLP1R; the disease is atherosclerosis.